HRP20220749T1 - Sastav koji sadrži apoaequorin za upotrebu u postupku liječenja smrti živčanih stanica od ishemije oralnom primjenom - Google Patents
Sastav koji sadrži apoaequorin za upotrebu u postupku liječenja smrti živčanih stanica od ishemije oralnom primjenom Download PDFInfo
- Publication number
- HRP20220749T1 HRP20220749T1 HRP20220749TT HRP20220749T HRP20220749T1 HR P20220749 T1 HRP20220749 T1 HR P20220749T1 HR P20220749T T HRP20220749T T HR P20220749TT HR P20220749 T HRP20220749 T HR P20220749T HR P20220749 T1 HRP20220749 T1 HR P20220749T1
- Authority
- HR
- Croatia
- Prior art keywords
- apoaequorin
- cell death
- neuronal cell
- ischemia
- treatment
- Prior art date
Links
- 108010041089 apoaequorin Proteins 0.000 title claims 6
- 230000016273 neuron death Effects 0.000 title claims 3
- 239000000203 mixture Substances 0.000 title claims 2
- 208000028867 ischemia Diseases 0.000 title 1
- 210000002569 neuron Anatomy 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (2)
1. Apoaequorin za upotrebu u postupku liječenja koji obuhvaća prekondicioniranje neurona u svrhu smanjenja smrti živčanih stanica poslije ishemije kod subjekta koji je podložan ishemijskoj smrti stanica, spomenuti apoaequorin je osiguran u terapeutski efikasnoj dozi za prekondicioniranje neurona kod subjekta kako bi se smanjila smrt živčanih stanica i gdje je taj apoaequorin davan oralno u obliku nutricionističkog sastava.
2. Apoaequorin za upotrebu prema zahtjevu 1, gdje je apoaequorin u jediničnoj dozi izabranoj između tablete ili kapsule.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462078099P | 2014-11-11 | 2014-11-11 | |
| PCT/US2015/060116 WO2016077437A1 (en) | 2014-11-11 | 2015-11-11 | Apoaequorin-containing compositions and methods of using same to treat neuronal inflammation |
| EP15858766.7A EP3217998B1 (en) | 2014-11-11 | 2015-11-11 | Apoaequorin-containing compositions for use in a method for the treatment of neuronal cell death from ischemia by oral administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220749T1 true HRP20220749T1 (hr) | 2022-09-02 |
Family
ID=55954981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220749TT HRP20220749T1 (hr) | 2014-11-11 | 2015-11-11 | Sastav koji sadrži apoaequorin za upotrebu u postupku liječenja smrti živčanih stanica od ishemije oralnom primjenom |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20180214516A1 (hr) |
| EP (1) | EP3217998B1 (hr) |
| JP (1) | JP6861162B2 (hr) |
| KR (1) | KR20170072350A (hr) |
| CN (1) | CN107106649A (hr) |
| AU (2) | AU2015346430B2 (hr) |
| BR (1) | BR112017009599A2 (hr) |
| CA (1) | CA2966891C (hr) |
| DK (1) | DK3217998T3 (hr) |
| ES (1) | ES2910021T3 (hr) |
| HK (2) | HK1243343A1 (hr) |
| HR (1) | HRP20220749T1 (hr) |
| HU (1) | HUE059107T2 (hr) |
| IL (1) | IL252070B (hr) |
| LT (1) | LT3217998T (hr) |
| MA (1) | MA40959A (hr) |
| MX (1) | MX2017006063A (hr) |
| NZ (1) | NZ731340A (hr) |
| PL (1) | PL3217998T3 (hr) |
| PT (1) | PT3217998T (hr) |
| RS (1) | RS63269B1 (hr) |
| SG (2) | SG10202108723PA (hr) |
| SI (1) | SI3217998T1 (hr) |
| WO (1) | WO2016077437A1 (hr) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ214563A (en) * | 1984-12-31 | 1991-05-28 | Univ Georgia | Production of apoaeqorin using recombinant dna |
| CA2717322C (en) * | 2008-03-11 | 2017-07-11 | Quincy Bioscience, Llc | Apoaequorin-containing compositions and methods of using same |
| US20110130336A1 (en) | 2009-10-16 | 2011-06-02 | Quincy Bioscience, Llc | Method of treating ischemic injury using apoaequorin |
| DK2780027T3 (en) * | 2011-11-15 | 2017-09-25 | Quincy Bioscience Llc | Apoaequorin for limiting ischemia-induced nerve damage. |
| PT2900253T (pt) * | 2012-09-27 | 2019-02-25 | Quincy Bioscience Llc | Métodos para aliviar os sintomas da esclerose múltipla baseados em composições contendo apoequorina |
-
2015
- 2015-11-10 MA MA040959A patent/MA40959A/fr unknown
- 2015-11-11 CN CN201580061431.1A patent/CN107106649A/zh active Pending
- 2015-11-11 ES ES15858766T patent/ES2910021T3/es active Active
- 2015-11-11 US US15/524,811 patent/US20180214516A1/en active Pending
- 2015-11-11 JP JP2017544569A patent/JP6861162B2/ja active Active
- 2015-11-11 PT PT158587667T patent/PT3217998T/pt unknown
- 2015-11-11 EP EP15858766.7A patent/EP3217998B1/en active Active
- 2015-11-11 SI SI201531841T patent/SI3217998T1/sl unknown
- 2015-11-11 KR KR1020177015570A patent/KR20170072350A/ko not_active Application Discontinuation
- 2015-11-11 AU AU2015346430A patent/AU2015346430B2/en active Active
- 2015-11-11 IL IL252070A patent/IL252070B/en unknown
- 2015-11-11 HR HRP20220749TT patent/HRP20220749T1/hr unknown
- 2015-11-11 MX MX2017006063A patent/MX2017006063A/es unknown
- 2015-11-11 LT LTEPPCT/US2015/060116T patent/LT3217998T/lt unknown
- 2015-11-11 HU HUE15858766A patent/HUE059107T2/hu unknown
- 2015-11-11 RS RS20220529A patent/RS63269B1/sr unknown
- 2015-11-11 WO PCT/US2015/060116 patent/WO2016077437A1/en active Application Filing
- 2015-11-11 PL PL15858766T patent/PL3217998T3/pl unknown
- 2015-11-11 BR BR112017009599A patent/BR112017009599A2/pt active Search and Examination
- 2015-11-11 NZ NZ731340A patent/NZ731340A/en unknown
- 2015-11-11 SG SG10202108723PA patent/SG10202108723PA/en unknown
- 2015-11-11 SG SG11201703690XA patent/SG11201703690XA/en unknown
- 2015-11-11 DK DK15858766.7T patent/DK3217998T3/da active
- 2015-11-11 CA CA2966891A patent/CA2966891C/en active Active
-
2018
- 2018-02-28 HK HK18102921.0A patent/HK1243343A1/zh unknown
- 2018-03-19 HK HK18103784.4A patent/HK1244223A1/zh unknown
- 2018-12-17 AU AU2018279057A patent/AU2018279057A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017535607A (ja) | 2017-11-30 |
| WO2016077437A1 (en) | 2016-05-19 |
| PL3217998T3 (pl) | 2022-07-11 |
| CN107106649A (zh) | 2017-08-29 |
| NZ731340A (en) | 2018-11-30 |
| LT3217998T (lt) | 2022-04-11 |
| CA2966891A1 (en) | 2016-05-19 |
| SI3217998T1 (sl) | 2022-07-29 |
| BR112017009599A2 (pt) | 2017-12-19 |
| JP6861162B2 (ja) | 2021-04-21 |
| HK1244223A1 (zh) | 2018-08-03 |
| EP3217998A4 (en) | 2018-06-27 |
| AU2015346430A1 (en) | 2017-05-25 |
| HUE059107T2 (hu) | 2022-10-28 |
| EP3217998A1 (en) | 2017-09-20 |
| IL252070B (en) | 2022-06-01 |
| MX2017006063A (es) | 2017-07-27 |
| AU2015346430B2 (en) | 2019-01-03 |
| KR20170072350A (ko) | 2017-06-26 |
| SG10202108723PA (en) | 2021-09-29 |
| ES2910021T3 (es) | 2022-05-11 |
| CA2966891C (en) | 2023-07-04 |
| PT3217998T (pt) | 2022-04-05 |
| MA40959A (fr) | 2017-09-19 |
| RS63269B1 (sr) | 2022-06-30 |
| HK1243343A1 (zh) | 2018-07-13 |
| EP3217998B1 (en) | 2022-03-23 |
| US20180214516A1 (en) | 2018-08-02 |
| SG11201703690XA (en) | 2017-06-29 |
| AU2018279057A1 (en) | 2019-01-17 |
| IL252070A0 (en) | 2017-07-31 |
| DK3217998T3 (da) | 2022-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52257A (fr) | Compositions pharmaceutiques comprenant blautia et leur administration orale | |
| IL255509B (en) | Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases | |
| JP2014141525A5 (hr) | ||
| HRP20230584T1 (hr) | Prolijekovi gemcitabina | |
| EP3556369A4 (en) | ORAL PHARMACEUTICAL COMPOSITION WITH DELAYED AND CONTROLLED RELEASE OF OLAPARIB AND THEIR USE | |
| PT3412660T (pt) | Derivado de sulfonamida e composição farmacêutica contendo o mesmo | |
| IL265970B (en) | Sulfoxyalkyl organonitro compounds and related compounds and pharmaceutical preparations for use in medicine | |
| GB201620066D0 (en) | Solid Pharmaceutical dosage formulations and processes | |
| CO2017006898A2 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| EP3403658C0 (en) | COMPOSITION FOR THE TREATMENT OF NEUROINFLAMMATORY DISEASES CONTAINING NEURAL STEM CELLS OR THEIR SECRETOME AS ACTIVE INGREDIENT | |
| CO2016003340A2 (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| CL2016000026A1 (es) | Nuevos derivados de azabencimidazol | |
| IN2014MU01042A (hr) | ||
| MA52644A (fr) | Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation | |
| HK1255313A1 (zh) | 含有培美曲塞或其藥學上可接受的鹽的穩定藥物組合物 | |
| WO2015086838A3 (en) | A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation | |
| SG10202008700VA (en) | α-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
| EP3480186A4 (en) | NEW ARYLETE HAND DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREFORE AS AN ACTIVE SUBSTANCE | |
| PH12018500817A1 (en) | Pharmaceutical composition comprising metformin and lobeglitazone | |
| HRP20220749T1 (hr) | Sastav koji sadrži apoaequorin za upotrebu u postupku liječenja smrti živčanih stanica od ishemije oralnom primjenom | |
| JP2016513680A5 (hr) | ||
| HUE054241T2 (hu) | Stabil gyógyszerkészítmények topikális beadásra és alkalmazásuk | |
| EP3888647A4 (en) | EZH1/2 DUAL INHIBITOR CONTAINING PHARMACEUTICAL COMPOSITION FOR USE AS COMBINATION MEDICINAL PRODUCT | |
| IL275806A (en) | Immediate-release pharmaceutical preparations containing ketopropan lysine salt | |
| JP2017517574A5 (hr) |